Filing Flows

Filing Flows › Companies › Inhibrx Biosciences › Cash flow

Inhibrx Biosciences cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$29.9M in Q2 2026 · −$132M over twelve months

Operating cash flow−$29.9M
Free cash flow−$29.9M

Analysis

In Q2 2026, Inhibrx Biosciences generated −$29.9M of operating cash flow. That is $36K more than in Q2 2025 (−$30.0M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$132M; the largest uses were operating cash flow ($132M), capital spending ($10K); besides operations, cash came from net borrowing (+) / repaid (−) ($75.0M), shares issued ($3.7M); the cash balance fell by $53.2M.

Operating cash flow was −$29.9M against net income of −$36.6M. The largest differences: stock-based pay +$3.1M, payables +$1.0M, depreciation & amortization +$523K.

Free cash flow

Inhibrx Biosciences: free cash flow by quarterInhibrx Biosciences: free cash flow by quarter−$30.5MQ3 2024−$43.7MQ4 2024−$35.9MQ1 2025−$30.0MQ2 2025−$33.8MQ3 2025−$30.1MQ4 2025−$38.0MQ1 2026−$29.9MQ2 2026
Operating cash flow less capital spending.
Inhibrx Biosciences: operating cash flow against capital spendingInhibrx Biosciences: operating cash flow against capital spendingOperating cash flowCapital spending−$30.3M$247KQ3 2024−$43.7M$16KQ4 2024−$35.9M$21KQ1 2025−$30.0M$0Q2 2025−$33.8M$10KQ3 2025−$30.1M$0Q4 2025−$38.0M$0Q1 2026−$29.9M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$29.9M, Capital spending $0.

Capital allocation, year by year

Inhibrx Biosciences: where the cash came from (up) and went (down), by fiscal yearInhibrx Biosciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingFY2023: Operating cash flow −$193MFY2023: Shares issued $2.3MFY2023: Capital spending −$4.6M$2.3MFY2023FY2024: Operating cash flow −$194MFY2024: Shares issued $71.7MFY2024: Capital spending −$2.6M$71.7MFY2024FY2025: Operating cash flow −$130MFY2025: Net borrowing $100MFY2025: Shares issued $1.6MFY2025: Asset sales $3KFY2025: Capital spending −$31K$102MFY2025
Over these 3 years operating cash flow totalled −$518M; the largest uses were operating cash flow ($518M) and capital spending ($7.2M). Cash-flow statements as filed.

Where the cash came from and went

Inhibrx Biosciences: sources (+) and uses (−) of cash, Q2 2026Inhibrx Biosciences: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$29.9MCash drawn (+) / kept (−)$28.3MShares issued$1.6M
Inhibrx Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Inhibrx Biosciences: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$132MNet borrowing (+) / repaid (−)$75.0MCash drawn (+) / kept (−)$53.2MShares issued$3.7MCapital spending−$10KOther investing$3K

From profit to cash

Inhibrx Biosciences: net income to operating cash flow, Q2 2026Inhibrx Biosciences: net income to operating cash flow, Q2 2026Net income−$36.6MDepreciation & amortization$523KStock-based pay$3.1MPayables$1.0MAccrued liabilities$431KPrepaid and other assets$371KOperating cash flow−$29.9M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$29.9M——$1.6M$28.3M−$29.9M
Q1 2026−$38.0M—$75.0M$471K−$37.4M−$38.0M
Q4 2025−$30.1M——$1.3M$28.9M−$30.1M
Q3 2025−$33.8M−$10K—$352K$33.5M−$33.8M
Q2 2025−$30.0M———$30.0M−$30.0M
Q1 2025−$35.9M−$21K$100M—−$63.9M−$35.9M
Q4 2024−$43.7M−$16K——$43.7M−$43.7M
Q3 2024−$30.3M−$247K——$30.5M−$30.5M

Inhibrx Biosciences: income statement and cash flow

Inhibrx Biosciences, Q2 2025: revenue $1.3M (13× year over year). The chart follows the revenue to costs, profit and cash.

Inhibrx Biosciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.